Abstract
Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1=1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1=1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1=0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.
| Original language | English (US) |
|---|---|
| Journal | International Journal of Cancer |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Breast cancer
- Epidemiology
- Grade
- Hormone therapy
- KI67
- Nulliparity
- Obesity
- Proliferation
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. / Abubakar, Mustapha; Chang-Claude, Jenny; Ali, H. Raza; Chatterjee, Nilanjan; Coulson, Penny; Daley, Frances; Blows, Fiona; Benitez, Javier; Milne, Roger L.; Brenner, Hermann; Stegmaier, Christa; Mannermaa, Arto; Rudolph, Anja; Sinn, Peter; Couch, Fergus J; Devilee, Peter; Tollenaar, Rob A.E.M.; Seynaeve, Caroline; Figueroa, Jonine; Lissowska, Jolanta; Hewitt, Stephen; Hooning, Maartje J.; Hollestelle, Antoinette; Foekens, Renée; Koppert, Linetta B.; Bolla, Manjeet K.; Wang, Qin; Jones, Michael E.; Schoemaker, Minouk J.; Keeman, Renske; Easton, Douglas F.; Swerdlow, Anthony J.; Sherman, Mark E.; Sherman, Mark E.; Pharoah, Paul D.; Garcia-Closas, Montserrat.
In: International Journal of Cancer, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation
AU - Abubakar, Mustapha
AU - Chang-Claude, Jenny
AU - Ali, H. Raza
AU - Chatterjee, Nilanjan
AU - Coulson, Penny
AU - Daley, Frances
AU - Blows, Fiona
AU - Benitez, Javier
AU - Milne, Roger L.
AU - Brenner, Hermann
AU - Stegmaier, Christa
AU - Mannermaa, Arto
AU - Rudolph, Anja
AU - Sinn, Peter
AU - Couch, Fergus J
AU - Devilee, Peter
AU - Tollenaar, Rob A.E.M.
AU - Seynaeve, Caroline
AU - Figueroa, Jonine
AU - Lissowska, Jolanta
AU - Hewitt, Stephen
AU - Hooning, Maartje J.
AU - Hollestelle, Antoinette
AU - Foekens, Renée
AU - Koppert, Linetta B.
AU - Bolla, Manjeet K.
AU - Wang, Qin
AU - Jones, Michael E.
AU - Schoemaker, Minouk J.
AU - Keeman, Renske
AU - Easton, Douglas F.
AU - Swerdlow, Anthony J.
AU - Sherman, Mark E.
AU - Sherman, Mark E.
AU - Pharoah, Paul D.
AU - Garcia-Closas, Montserrat
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1=1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1=1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1=0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.
AB - Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1=1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1=1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1=0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.
KW - Breast cancer
KW - Epidemiology
KW - Grade
KW - Hormone therapy
KW - KI67
KW - Nulliparity
KW - Obesity
KW - Proliferation
UR - http://www.scopus.com/inward/record.url?scp=85044738114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044738114&partnerID=8YFLogxK
U2 - 10.1002/ijc.31352
DO - 10.1002/ijc.31352
M3 - Article
C2 - 29492969
AN - SCOPUS:85044738114
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
ER -